SCHEMBL1949348

SCHEMBL1949348

Cn1ccc(S(=O)(=O)N(Cc2ccccc2)c2ccc3c(c2)CCNC3)n1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 5/20 0.44
HTR2B P41595 2/20 0.38
CYP3A4 P08684 1/20 0.37
HTR6 P50406 2/20 0.36
HTR1A P08908 1/20 0.36
HTR2A P28223 1/20 0.36
HTR7 P34969 1/20 0.36
DRD3 P35462 1/20 0.36
PNMT P11086 2/20 0.35
NR1I2 O75469 1/20 0.35
MLNR O43193 1/20 0.35
LMNA P02545 2/20 0.33
ALDH1A1 P00352 1/20 0.33
WEE1 P30291 1/20 0.33
NMT1 P30419 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
PGR P06401 1/20 0.33
NR3C1 P04150 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1951619 0.83 PARP11 (0.45) HTR2CHTR6HTR1AHTR2AHTR7
SCHEMBL1948823 0.80 HPGD (0.48) LMNAALDH1A1
SCHEMBL1948767 0.76 HPGD (0.45) LMNAALDH1A1
SCHEMBL1949516 0.76 CNR2 (0.38) LMNAALDH1A1
SCHEMBL1949299 0.76 CNR2 (0.38) HTR2CHTR2BHTR7LMNAALDH1A1
SCHEMBL1952905 0.76 GRM5 (0.39) HTR2CHTR6HTR1AHTR2AHTR7
SCHEMBL1951603 0.76 HPGD (0.44) LMNAALDH1A1
SCHEMBL1948512 0.76 ESR2 (0.46) LMNAALDH1A1
SCHEMBL1948562 0.75 HPGD (0.47) LMNAALDH1A1
SCHEMBL1949528 0.75 HPGD (0.43) LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438055-B1 DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS JAPAN TOBACCO INC (JP) 2018-10-24 EP disclosed
US-8426442-B2 Compounds XENTION LTD (GB) 2013-04-23 US disclosed
EP-2438055-A1 DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS Xention Limited (GB) 2012-04-11 EP disclosed
US-20110136860-A1 Compounds XENTION LTD. (GB) 2011-06-09 US disclosed
WO-2010139967-A1 DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS XENTION LIMITED (GB) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136860-A1 Compounds NR3C2, NR5A1, NR0B2 HTR2C 852/4885HTR2B 1437/4885CYP3A4 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.